Key facts
- It has raised $5.7M across 1 recorded rounds; the latest was Seed Round ($2.1M) in Jan 2022.
- Notable investors include Scottish Enterprise, The Scottish National Investment Bank, Mark Bamforth, SIS Ventures, Tern (Private Equity).
- Talking Medicines has filed 1 Form D with the SEC, most recently Mar 2022 ($2.1M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Talking Medicines
Funding rounds
1 roundsAbout Talking Medicines
Developer of a healthcare technology tool designed to capture, curate, and structure the voice of the patient on launched medicines. The company's platform uses a collection of artificial intelligence, machine learning, and neuro-linguistic programming technological tools to capture and analyze the conversations and behaviors of patients at home and map the patient voice to regulate medicine information and build data points to deliver trends and patterns of usage across medicines and brands, enabling pharmaceutical companies to identify patterns of data across multiple medicines and their therapeutic areas of interest.
- Sector
- Healthcare
- HQ
- Glasgow, United Kingdom
- Founded
- 2013
- Employees
- 39
- Website
- talkingmedicines.com/
- Ownership
- Privately Held (backing)
Talking Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Talking Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Talking Medicines in its N-PORT filings yet. We sweep new filings monthly.